Vinay Prasad, M.D., has rejoined the FDA, the latest turn in a monthslong stretch of leadership turnover at the agency. | “At ...

With the FDA approval of its zongertinib in certain non-small cell lung cancer (NSCLC) patients, 175-year-old Boehringer ...

After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona ...

Lilly has been chasing—and gaining on—its chief metabolic medicine rival Novo Nordisk and its counterpart GLP-1s Ozempic and ...

Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while ...

The Centers for Disease Control and Prevention debuted a new public health awareness campaign this week focused on educating ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

Contract manufacturers have carved out a lucrative niche within the biopharma industry, and the value of their collective ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...

The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with ...